Is UNII-2BMD2GNA4V Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-2BMD2GNA4V? Is UNII-2BMD2GNA4V safe for nursing mother and child? Does UNII-2BMD2GNA4V extracts into breast milk? Does UNII-2BMD2GNA4V has any long term or short term side effects on infants? Can UNII-2BMD2GNA4V influence milk supply or can UNII-2BMD2GNA4V decrease milk supply in lactating mothers?

• DrLact safety Score for UNII-2BMD2GNA4V is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of UNII-2BMD2GNA4V may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that UNII-2BMD2GNA4V may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using UNII-2BMD2GNA4V .
• It is recommended to evaluate the advantage of not breastfeeding while using UNII-2BMD2GNA4V Vs not using UNII-2BMD2GNA4V And continue breastfeeding.
• While using UNII-2BMD2GNA4V Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

It is excreted into breast milk in amounts that may be clinically significant and can be as high as a half of that reached in mother’s plasma and up to one third of the therapeutic level in the infant. In infants and newborns (5 days), premature babies and dehydrated or infected infants, who may show reduced clearance mechanisms for UNII-2BMD2GNA4V, there have been reports of clear signs of UNII-2BMD2GNA4V toxicity caused by ingestion of breast milk: cyanosis, lethargy, hypotonia or slight increase in TSH. However, there are numerous cases of infants whose mothers were on UNII-2BMD2GNA4V who did not show any clinical, growth or neurodevelopmental problem at the short or long term. Breastfeeding is less risky for healthy term infants whose mothers are treated with UNII-2BMD2GNA4V when she or her family has capacity enough to monitor the occurrence of adverse effects, medical supervision and, whenever necessary, monitoring of UNII-2BMD2GNA4V levels in the mother-infant dyad. Mothers should stop taking UNII-2BMD2GNA4V 1 to 2 days before delivery or cesarean section in order to decrease plasma levels in the newborn. UNII-2BMD2GNA4V may be, or not, a cause of increased Prolactin and galactorrhea.

Although UNII-2BMD2GNA4V appears on many lists of drugs contraindicated during breastfeeding, other sources do not consider it an absolute contraindication, especially in infants over 2 months of age and during UNII-2BMD2GNA4V monotherapy.[1][2][3][4] Numerous reports exist of infants who were breastfed during maternal UNII-2BMD2GNA4V therapy without any signs of toxicity or developmental problems. Most were breastfed from birth and some continued to nurse for up to 1 year of maternal UNII-2BMD2GNA4V therapy. Limited data suggest that UNII-2BMD2GNA4V in milk can adversely affect the infant when its elimination is impaired, as in dehydration or in newborn or premature infants. Neonates may also have transplacentally acquired serum UNII-2BMD2GNA4V levels. Because maternal UNII-2BMD2GNA4V requirements and dosage may be increased during pregnancy, maternal serum levels should be monitored frequently postpartum and dosage reduced as necessary to avoid excessive infant exposure via breastmilk.[5] The long-term effects of UNII-2BMD2GNA4V on infants are not certain, but limited data indicate no obvious problems in growth and development.[6] UNII-2BMD2GNA4V may be used in mothers of fullterm infants who are willing and able to monitor their infants. Discontinuing UNII-2BMD2GNA4V 24 to 48 hours before Cesarean section delivery or at the onset of spontaneous labor and resuming the prepregnancy UNII-2BMD2GNA4V dose immediately after delivery should minimize the infant's serum UNII-2BMD2GNA4V concentration at birth.[7] Some investigators recommend monitoring infant serum UNII-2BMD2GNA4V, serum creatinine, BUN, and TSH in intervals ranging from "periodic" to every 4 to 12 weeks during breastfeeding and maternal UNII-2BMD2GNA4V therapy.[3][8][9] However, others recommend close pediatric follow-up of the infant and only selective laboratory monitoring as clinically indicated.[7] Breastfeeding should be discontinued immediately and the infant evaluated if the infant appears restless or lethargic or has feeding problems.[7]

In older reports, at least 24 infants have been reported to have been breastfed during maternal UNII-2BMD2GNA4V therapy without any signs of toxicity or developmental problems. All were breastfed from birth and some continued to nurse for up to 6 months of maternal UNII-2BMD2GNA4V therapy.[9][11][12][13][17][18][20] A 5-day-old infant developed cyanosis, lethargy, ECG T-wave inversion probably caused by UNII-2BMD2GNA4V in breastmilk.[15] The mother had been receiving the long-acting diuretic chlorthalidone prior to delivery which probably decreased the infant's UNII-2BMD2GNA4V elimination and increased the neonate's UNII-2BMD2GNA4V serum levels. Another case of probable infant UNII-2BMD2GNA4V intoxication appeared only after the infant had a cold which may have led to dehydration and decreased UNII-2BMD2GNA4V excretion.[19][23] Two other infants had slight increases in thyrotropin (TSH) levels at 8 and 4 weeks of age, respectively, after UNII-2BMD2GNA4V exposure that began during pregnancy. Elevated TSH continued until maternal UNII-2BMD2GNA4V was stopped in one,[9] and normalized by 2 months postpartum in the other, despite continued exclusive breastfeeding.[20] Three mothers took UNII-2BMD2GNA4V carbonate during pregnancy and breastfeeding. The first infant was born to a mother who also took bupropion 300 mg and levothyroxine 50 to 75 mcg daily. She breastfed beyond 1 year of age. Her infant did not regain birth weight by 15 days of age, was somewhat hypotonic at 2 months of age, and was treated for gross and fine motor delay for the first year of life. The mother had a second infant on the same drug regimen. She exclusively breastfed her infant who developed normally without hypotonia. A second mother was taking a UNII-2BMD2GNA4V dosage of 900 mg daily. Her infant gained weight slowly, but weight gain increased with breastfeeding support and she exclusively breastfed her infant for 4 months. A third mother was taking 1350 mg of UNII-2BMD2GNA4V daily as well as escitalopram 10 mg, levothyroxine 25 mcg and heparin (dosage not stated) daily during pregnancy and breastfeeding. Her infant was normal and was exclusively breastfed until 8 weeks of age when the maternal serum UNII-2BMD2GNA4V concentration was excessive at 2.0 mEq/L. Breastfeeding was withheld for 2 days and the dosage lowered to 600 mg daily. She then breastfed successfully until 7 months of age.[7] A woman with bipolar disorder took prolonged-release UNII-2BMD2GNA4V carbonate 400 mg every 12 hours during pregnancy and postpartum. She breastfed her infant exclusively for 33 days, but introduced supplements for 16 days because of slow weight gain. After the 16 days, she exclusively breastfed her infant until 2.5 months of age, when mixed feeding was begun. The infant was monitored at 17 days, 1 month, 3.5 months and 5.5 months of age. No infant side effects were observed at any time. UNII-2BMD2GNA4V levels were not detectable, and serum creatinine and thyroid-stimulating hormone levels were normal.[22]

UNII-2BMD2GNA4V increases serum prolactin.[24][25][26] Galactorrhea was reported in a women taking UNII-2BMD2GNA4V carbonate for 50 days. Lactation ceased with UNII-2BMD2GNA4V discontinuation.[26] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.